NCT05942508View on ClinicalTrials.gov

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Limited Stage Small Cell Lung CancerNot Progressed After First-line Chemoradiotherapy

Interventions

DRUG

TQB2450 Injection + Anlotinib Hydrochloride Capsules

Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody

Trial Locations (1)

250117

RECRUITING

Cancer Hospital Affiliated to Shandong First Medical University, Jinan

All Listed Sponsors

lead

Jinming Yu

OTHER